India to Oman: Arishta Export Trade Route

To import finished pharmaceutical formulations containing Arishta into Oman, manufacturers must adhere to the Gulf Health Council's (GHC) regulatory framework, which is harmonized across Gulf Cooperation Council (GCC) member states. The registration process involves several critical steps:

1. Product Registration: Manufacturers are required to submit a comprehensive dossier for each pharmaceutical product. This dossier should be formatted according to the Common Technical Document (CTD) or electronic CTD (eCTD) standards, encompassing modules on administrative information, quality, safety, and efficacy.

2. Submission and Review: The dossier is submitted to Oman's Ministry of Health (MOH), specifically the Directorate General for Pharmaceutical Affairs and Drug Control. The review process evaluates the product's purpose, country of origin, anticipated demand, and the presence of similar products in the market. Timelines for approval can vary; however, under the India-Oman Comprehensive Economic Partnership Agreement (CEPA) signed in December 2025, products approved by recognized stringent authorities (e.g., USFDA, EMA, UK MHRA, TGA) may benefit from expedited marketing authorizations within 90 days, provided complete assessment dossiers are submitted. If inspections are necessary, approvals are targeted within 270 working days.

3. Fees: While specific product registration fees are not publicly detailed, they are typically outlined by the MOH and may vary based on the product category and complexity.

4. GMP Inspection: Indian manufacturing facilities producing Arishta formulations must comply with Good Manufacturing Practices (GMP) as per the Gulf Cooperation Council (GCC-GMP) guidelines and the World Health Organization (WHO-GMP) standards. The MOH may conduct inspections of these facilities to ensure compliance. Under the CEPA, there is an acceptance of GMP certificates and inspection outcomes from recognized authorities, which can streamline the approval process.

Indian exporters of Arishta formulations must adhere to stringent GMP standards to supply products to Oman. As of January 2024, India's Ministry of Health revised Schedule M of the Drugs and Cosmetics Rules to align with WHO-GMP standards. This revision introduced requirements such as a pharmaceutical quality system (PQS), quality risk management (QRM), product quality review (PQR), and validation of equipment. Manufacturers are mandated to comply with these updated GMP standards by December 31, 2025, or face potential closure.

Specific information regarding which Indian facilities are currently approved to export to Oman is not publicly available. However, compliance with the updated GMP standards is essential for market access. Recent regulatory actions have emphasized the importance of adherence to these standards, with state authorities in India issuing warning notices to non-compliant manufacturers, indicating potential operational shutdowns if compliance is not achieved by the stipulated deadline.

Several significant regulatory developments have occurred between 2024 and 2026 affecting Indian pharmaceutical exports to Oman:

1. India-Oman CEPA: Signed in December 2025, this agreement provides zero-duty access for key finished medicines and active pharmaceutical ingredients. It introduces regulatory fast-tracking for products approved by recognized stringent authorities, with potential marketing authorizations within 90 days without prior inspections, subject to complete assessment dossiers. Acceptance of GMP certificates and inspection outcomes from these authorities further streamlines the approval process.

2. GMP Compliance Deadline: The Indian Ministry of Health's revision of Schedule M in January 2024 mandated that all pharmaceutical manufacturers, including Micro, Small, and Medium Enterprises (MSMEs), comply with updated GMP standards by December 31, 2025. Non-compliance may result in operational shutdowns, as state authorities have begun issuing warning notices to manufacturers failing to meet these requirements.

3. Unified Industrial Regulation Law: In February 2026, Oman implemented the Unified Industrial Regulation Law for GCC countries, aiming to enhance the industrial environment, encourage investment, and ensure compliance with health and environmental standards. This law regulates the industrial sector, promotes development, and aligns with GCC economic policies toward manufacturing, impacting pharmaceutical manufacturing and importation processes.

These developments collectively aim to enhance the quality and safety of pharmaceutical products imported into Oman, streamline regulatory processes, and foster stronger trade relations between India and Oman.

Arishta formulations, integral to the Ayurvedic system, are utilized for various therapeutic purposes. While specific market size data for Arishta in Oman is not readily available, the broader pharmaceutical market provides context. In 2024, Oman's pharmaceutical market was valued at approximately USD 302.84 million, with projections indicating growth to USD 473.71 million by 2031, reflecting a compound annual growth rate (CAGR) of 6.6%. This expansion is driven by increased healthcare expenditure, a growing aging population, and a rising prevalence of chronic diseases. The government's strategic investments under Oman Vision 2040 have significantly enhanced healthcare infrastructure, including the development of new hospitals and medical facilities, thereby improving access to healthcare services.

Oman's pharmaceutical sector relies heavily on imports to meet domestic demand, with India being a primary supplier. The trade data indicates that finished pharmaceutical formulations containing Arishta from India to Oman accounted for USD 0.1 million across 83 shipments, representing 3.6% of India's total Arishta formulation exports valued at USD 1.4 million. This underscores Oman's dependence on imported Ayurvedic formulations to fulfill its healthcare needs.

Oman maintains a 0% MFN import duty rate for pharmaceutical products classified under HS code 30049011, which includes finished formulations containing Arishta. This exemption aligns with Oman's commitment to ensuring the availability of essential medicines at affordable prices. Additionally, Oman has a Free Trade Agreement (FTA) with India, further facilitating the import of pharmaceutical products by eliminating trade barriers and promoting bilateral trade relations. There are no anti-dumping duties imposed on pharmaceutical imports under this HS code, ensuring a competitive market environment.

India is the predominant supplier of Arishta formulations to Oman, with the trade data highlighting that Indian exports of these products to Oman constitute 3.6% of India's total Arishta formulation exports. The primary exporters are The Arya Vaidya Pharmacy (Coimbatore) Limited, and the main importer in Oman is Rawafed Muscat National. While specific data on other countries supplying Arishta formulations to Oman is limited, India's significant share indicates its dominant position in this niche market.

Regarding pricing, Indian pharmaceutical products, including Ayurvedic formulations, are generally competitively priced compared to those from manufacturers in the European Union or China. This cost advantage, coupled with the established trade relations and the FTA between India and Oman, positions Indian suppliers favorably in the Omani market.

India's pharmaceutical industry is a global leader, ranking third worldwide in terms of volume and 11th by value. In the fiscal year 2024–25, India's pharmaceutical exports reached $30.47 billion, marking a 9.4% increase over the previous year. This growth underscores India's robust manufacturing capabilities and its pivotal role in supplying affordable, high-quality medicines globally.

The country boasts over 10,500 manufacturing units and more than 3,000 pharmaceutical companies, producing over 60,000 generic brands across nearly 60 therapeutic categories. This extensive infrastructure enables large-scale production of finished dosage forms, including tablets, capsules, syrups, and injections containing Arishta.

India's cost advantages stem from economies of scale, a skilled workforce, and a favorable regulatory environment. The nation has the highest number of US FDA-approved plants outside the USA, ensuring compliance with stringent international quality standards. This regulatory compliance, combined with cost efficiencies, positions India as a preferred source for Arishta formulations globally.

When comparing Arishta formulation exports, India offers a compelling balance of cost and quality. While specific price per unit data for Arishta formulations is not publicly available, India's pharmaceutical exports are known for their affordability without compromising quality. The country supplies approximately 20% of the global generic drug market, emphasizing its cost-effectiveness.

China, another major player in generic formulations, often competes on cost but may face challenges related to regulatory compliance and quality perception in certain markets. The European Union, known for branded generics, typically offers higher-priced products with a strong emphasis on quality.

In Oman, Indian pharmaceutical products are well-accepted due to their adherence to international quality standards and competitive pricing. India's track record of reliable supply and regulatory compliance further strengthens its position as a preferred supplier of Arishta formulations.

India's pharmaceutical industry has demonstrated consistent supply reliability, supported by its vast manufacturing capacity and robust infrastructure. The country has over 10,500 manufacturing units, many of which are WHO-GMP and US FDA-approved, ensuring adherence to international quality standards.

Packaging and cold chain capabilities are well-established, facilitating the export of various finished dosage forms, including those containing Arishta. While specific data on recent supply disruptions is limited, India's pharmaceutical sector has shown resilience, with exports growing by 9.4% in 2024–25 despite global challenges.

Top Indian formulation manufacturers continue to expand their capacities to meet growing global demand. This proactive approach ensures a steady supply of Arishta formulations to markets like Oman.

For Omani buyers sourcing Arishta formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks related to supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts. Indian suppliers often offer flexibility, but clear communication is essential to meet both parties' requirements.

• Payment Terms: Standard payment terms in India-Oman pharmaceutical trade include Letters of Credit (LC) and advance payments. Establish terms that balance cash flow considerations with supplier trust.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, quality certifications verification (such as WHO-GMP and US FDA approvals), and compliance with Omani regulatory requirements.

• Regulatory Compliance: Ensure that selected suppliers have a strong track record of regulatory compliance and can provide necessary documentation for Omani health authorities.

By implementing these strategies, Omani buyers can establish a reliable and cost-effective supply chain for Arishta formulations from India.

By meticulously following these guidelines, Omani companies can establish reliable partnerships with Indian Arishta manufacturers, ensuring the consistent supply of high-quality pharmaceutical formulations.